ClinicalTrials.gov record
Terminated Phase 3 Interventional

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

ClinicalTrials.gov ID: NCT00812240

Public ClinicalTrials.gov record NCT00812240. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 8:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Multicenter, Randomized, Open-label, Active-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Imatinib at 400 or 600 mg in Treatment of Patients With Gastro-intestinal Stromal Tumor in First Line Medical Treatment

Study identification

NCT ID
NCT00812240
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
AB Science
Industry
Enrollment
335 participants

Conditions and interventions

Interventions

  • Imatinib Drug
  • Masitinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2008
Primary completion
Jun 30, 2018
Completion
Jun 30, 2018
Last update posted
Jan 31, 2023

2009 – 2018

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
MD Anderson Cancer Center Orlando Florida 32806
The Emory Clinic Atlanta Georgia 30322
Henry Ford Health System Detroit Michigan 48202
Beth Israel Medical Center New York New York 10003
Ohio State University Columbus Ohio 43210
Cancer Centers of the Carolinas Greenville South Carolina 290605
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00812240, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 31, 2023 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00812240 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →